- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Immunomedics wins $1.5 million award
Immunomedics of Morris Plains, NJ, was awarded $1.5 million by an arbitration panel last month in relation to its dispute with Pharmacia & Upjohn. Immunomedics had charged Pharmacia with breach of contract after it terminated a sales and licensing
Immunomedics of Morris Plains, NJ, was awarded $1.5 million by an arbitration panel last month in relation to its dispute with Pharmacia & Upjohn. Immunomedics had charged Pharmacia with breach of contract after it terminated a sales and licensing agreement for U.S. and Canadian sales of its CEA-Scan monoclonal-antibody-based imaging agent (SCAN 9/11/96).
Pharmacia had gained rights to CEA-Scan when it acquired the parent company of Adria Laboratories, the original licensee, in 1993. Pharmacia in 1995 canceled the agreement, saying it was scaling back its oncology sales force. Although the $1.5 million is a welcome addition to Immunomedics' balance sheet, it is much lower than the $60 million in damages that the company requested. Mallinckrodt now has U.S. and Canadian rights to CEA-Scan.
In other Immunomedics news, the company reported that its Dutch subsidiary, Immunomedics Europe, has entered into a packaging and distribution agreement with Eli Lilly for its LeukoScan infectious imaging agent and other potential products. Eli Lilly will have European rights to the agent, which the European Union in February 1997 approved for imaging bone infection.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
